Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.
Olson R, Liu M, Bergman A, Lam S, Hsu F, Mou B, Berrang T, Mestrovic A, Chng N, Hyde D, Matthews Q, Lund C, Glick D, Pai H, Basran P, Carolan H, Valev B, Lefresene S, Tyldesley S, Schellenberg D.
Olson R, et al.
BMC Cancer. 2018 Oct 4;18(1):954. doi: 10.1186/s12885-018-4859-7.
BMC Cancer. 2018.
PMID: 30286739
Free PMC article.
Clinical Trial.